Dosimetric Impact of Inter-Fraction Variability in the Treatment of Breast Cancer: Towards New Criteria to Evaluate the Appropriateness of Online Adaptive Radiotherapy.

AI radiotherapy CBCT radiotherapy inter-fraction dose variation online adaptation predictive modeling

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 17 12 2021
accepted: 11 03 2022
entrez: 28 4 2022
pubmed: 29 4 2022
medline: 29 4 2022
Statut: epublish

Résumé

As a discipline in its infancy, online adaptive RT (ART) needs new ontologies and The study was focused on right breast cancer patients treated using standard adjuvant RT on an artificial intelligence (AI)-based linear accelerator. Patients were treated with daily CBCT images and without online adaptation, prescribing 40.05 Gy in 15 fractions, with four IMRT tangential beams. ESTRO guidelines were followed for the delineation on planning CT (pCT) of organs at risk and targets. For each patient, all the CBCT images were rigidly aligned to pCT: CTV and PTV were manually re-contoured and the original treatment plan was recalculated. Various radiological parameters were measured on CBCT images, to quantify inter-fraction variability present in each RT fraction after the couch shifts compensation. The variation of these parameters was correlated with the variation of V95% of PTV (ΔV95%) using the Wilcoxon Mann-Whitney test. Fractions where ΔV95% > 2% were considered as adverse events. A logistic regression model was calculated considering the most significant parameter, and its performance was quantified with a receiver operating characteristic (ROC) curve. A total of 75 fractions on 5 patients were analyzed. The body variation between daily CBCT and pCT along the beam axis with the highest MU was identified as the best predictor ( A novel strategy to identify treatment fractions that may benefit online ART was proposed. After image alignment, the measure of body difference between daily CBCT and pCT can be considered as an indirect estimator of V95% PTV variation: a difference larger than 3 mm will result in a V95% decrease larger than 2%. A larger number of observations is needed to confirm the results of this hypothesis-generating study.

Identifiants

pubmed: 35480103
doi: 10.3389/fonc.2022.838039
pmc: PMC9035849
doi:

Types de publication

Journal Article

Langues

eng

Pagination

838039

Informations de copyright

Copyright © 2022 Iezzi, Cusumano, Piccari, Menna, Catucci, D’Aviero, Re, Di Dio, Quaranta, Boschetti, Marras, Piro, Tomei, Votta, Valentini and Mattiucci.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

CA Cancer J Clin. 2019 Mar;69(2):127-157
pubmed: 30720861
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S3-9
pubmed: 20171515
J Appl Clin Med Phys. 2021 Oct;22(10):210-221
pubmed: 34529332
Radiother Oncol. 2020 Dec;153:55-66
pubmed: 32920005
Acta Oncol. 2013 May;52(4):703-10
pubmed: 23421926
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1021-30
pubmed: 18556141
Front Oncol. 2021 Aug 30;11:748685
pubmed: 34527596
J Appl Clin Med Phys. 2019 Jun;20(6):194-198
pubmed: 31055870
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):574-580
pubmed: 28581397
J Appl Clin Med Phys. 2022 Jan;23(1):e13479
pubmed: 34846098
Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):394-403
pubmed: 26678659
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1347-1356
pubmed: 32758641
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
Pract Radiat Oncol. 2021 Jan-Feb;11(1):e11-e21
pubmed: 32739438
Med Oncol. 2020 Apr 22;37(6):50
pubmed: 32323066
Phys Med. 2021 May;85:175-191
pubmed: 34022660
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):994-1003
pubmed: 28916139
J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83
pubmed: 18695137
Radiother Oncol. 2015 Jan;114(1):3-10
pubmed: 25630428
Radiat Oncol. 2021 May 4;16(1):84
pubmed: 33947429
Strahlenther Onkol. 2012 Jan;188(1):97-9
pubmed: 22234506
Oncologist. 2018 May;23(5):556-565
pubmed: 29472313
Clin Transl Radiat Oncol. 2019 Apr 08;18:98-101
pubmed: 31341983
Radiol Med. 2021 Mar;126(3):421-429
pubmed: 32833198
Clin Transl Radiat Oncol. 2019 Apr 02;18:54-59
pubmed: 31341976
Ann Oncol. 2010 Apr;21(4):723-728
pubmed: 19833817
J Appl Clin Med Phys. 2020 Nov;21(11):70-79
pubmed: 33089954
Biochem Med (Zagreb). 2011;21(3):203-9
pubmed: 22420233

Auteurs

Martina Iezzi (M)

Università Cattolica del Sacro Cuore, Rome, Italy.

Davide Cusumano (D)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Danila Piccari (D)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Sebastiano Menna (S)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Francesco Catucci (F)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Andrea D'Aviero (A)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Alessia Re (A)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Carmela Di Dio (C)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Flaviovincenzo Quaranta (F)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Althea Boschetti (A)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Marco Marras (M)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Domenico Piro (D)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Flavia Tomei (F)

UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Claudio Votta (C)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Vincenzo Valentini (V)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Gian Carlo Mattiucci (GC)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
UOC Radioterapia Oncologica, Mater Olbia Hospital, Olbia, Italy.

Classifications MeSH